Articles related to ANEMIA

This “Clinical Trials & Observations” report from Blood Advances (ASH)  explores the implications of the recently approved anemia treatment luspatercept, which can now be prescribed in the second-line setting after erythropoiesis-stimulating agents (ESAs) have failed or for patients who are not eligible because of high serum erythropoietin (sEPO) levels. A downloadable visual abstract helps paint the picture as well.

ASH Clinical News speaks with Maureen Achebe, MD, MPH, Clinical Director of the Non-Malignant Hematology Clinic at Brigham and Women’s Hospital in Boston, and other experts, about the safety and efficacy of IV iron products, how they are perceived in the community, and barriers to their use in the clinic. 

Can transfusion independence for multiple weeks be possible in patients with myelodysplastic syndromes? Read on to discover promising information you can share with your patients about reducing the severity of their anemia.